Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum
Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price gains.
Overview
Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy amid a year of sharp share price gains.
On June 9, 2026, Director Robert Mashal reported the acquisition of 25,000 shares of Nuvation Bio (NYSE:NUVB) through an open-market transaction, as disclosed in this SEC Form 4 filing.
Details
Transaction value based on SEC Form 4 reported price ($4.73).
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.